Search results for Bristol Myers Squibb

Analyst Report: Bristol-Myers Squibb Co

Analyst Report: Bristol-Myers Squibb Co

<![CDATA[Bristol Myers Squibb, Hengrui Pharma Form $15.2 Billion Strategic Drug Development Collaboration]]>

<![CDATA[Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand St...

Bristol-Myers Squibb Company 2026 Q1 - Results - Earnings Call Presentation

Bristol Myers, Hengrui Pharma Team Up in Global Drug Research Pact That Could Top $15B

Bristol Myers Squibb is paying $600 million up front to begin a 13-drug collaboration with Hengrui Pharma spanning oncology, hematology, and immunology. That tops a 12-drug pact GS...

Bristol-Myers Squibb: The Market Is Not Pricing The Growth Portfolio That Replaces The Patent Cliff

Bristol Myers Squibb inks $15B biobucks deal to bag Hengrui assets, tap China’s R&D speed

Bristol Myers Squibb has formed a broad partnership with Hengrui Pharma, paying $600 million upfront to advance 13 early-stage programs from across the two companies’ pipelines. Th...

Bristol Myers unveils data for one of its next-gen blood cancer drugs

Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.

Hengrui Pharma shares surge on $1 bln Bristol-Myers partnership

In Alzheimer’s, Bristol Myers sees big promise beyond amyloid

Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.

May 12 2026 - BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal

May 12 2026 - BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal admin Tue, 05/12/2026 - 12:10 Big deals lead the way today, with a massive BMS partners...

Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion

The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S. and Europe-based cou...

Cantor Fitzgerald Lifts Bristol Myers (BMY) Price Target but Flags Weak Q1 Catalyst

Cantor Fitzgerald Lifts Bristol Myers (BMY) Price Target but Flags Weak Q1 Catalyst

Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook

Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqemb...

Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target

Roche’s Foundation Medicine is deepening its longstanding ties with Bristol Myers Squibb as the companies team up on a new target.

Which Dividend Pharma Stock Should a Value Investor Choose Today?

Bristol Myers Squibb looks like a value buy, so long as its pipeline remains strong.

Bristol Myers Squibb-Pfizer Alliance to sell Eliquis on Mark Cuban’s Cost Plus Drugs

The Bristol Myers Squibb–Pfizer Alliance announced the launch of a collaboration with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) to offer Eliquis (apixaban) on CostPlusDru...

Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers

Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases.

Market Digest: BMY, SWX

Market Digest: BMY, SWX

BMS calls time on Zymeworks collab, ending work on phase 1 cancer bispecific

Bristol Myers Squibb has called time on a bispecific antibody partnership with Zymeworks that the Big Pharma inherited from Celgene.

Is Bristol Myers Squibb the Best Bargain in Big Pharma?

This pharma stock is cheap for a reason.